MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.620
-0.010 (-0.61%)
Mar 28, 2025, 4:00 PM EST - Market closed
Company Description
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.
Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.
The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Vlad Vitoc |
Contact Details
Address: 444 West Lake Street, Suite 1700 Chicago, Illinois 60606 United States | |
| Phone | 312 416 8592 |
| Website | maiabiotech.com |
Stock Details
| Ticker Symbol | MAIA |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001878313 |
| CUSIP Number | 552641102 |
| ISIN Number | US5526411021 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors |
| Jeffrey C. Himmelreich | Head of Finance |
| Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
| Linda Moreira | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 26, 2025 | 424B5 | Filing |
| Mar 21, 2025 | 8-K | Current Report |
| Mar 21, 2025 | 10-K | Annual Report |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 4, 2025 | D | Notice of Exempt Offering of Securities |
| Mar 3, 2025 | SCHEDULE 13G | Filing |